VRXA NASDAQ
Veraxa Biotech Holding AG
1W: -19.9%
1M: -18.1%
3M: -48.4%
YTD: -88.6%
$1.13
-0.06 (-5.04%)
Weekly Expected Move ±10.9%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$159.8M
52W Range1.105-27.36
Volume149,730
Avg Volume413,156
Beta0.26
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChristoph Antz
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2026-06-09
Websiteveraxa.com
Im Neuenheimer Feld 584
Heidelberg, ZH 69120
DE
Heidelberg, ZH 69120
DE
49 6221 3521330
About Veraxa Biotech Holding AG
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.
Latest News
VERAXA Biotech names Raju Willener as CFO
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
Recent Insider Trades
No insider trades found